Since HDAC6 transcript and protein expressions were increased after exposure to panobinostat in sensitive and resistant myeloma cells, we hypothesized that HDAC6 specific inhibitors might augment panobinostat efficacy. This evidence concerns the gene HDAC6 and plasma cell myeloma.